Abstract
The data on the safety and effectiveness of the use of the domestic immunomodulating preparation Polyoxidonium® (azoximer bromide) in children are summarized in the following pages. Polyoxidonium has an immunomodulatory (including interferon-inducing), detoxication and anti-inflammatory effect that allows the clinical course of the disease to be quickly alleviated and the natural immune response modulated. The clinical effectiveness of the drug in acute respiratory infections (ARI) in children, including those with allergic anamnesis. Recent studies have proven the effectiveness of the 7-day course of the preparation Polyoxidonium® for the treatment and prevention of ARI and influenza in children, starting at the age of 3 years, as evidenced by a rapid positive dynamics of clinical symptoms and a 2-fold decrease in ARI frequency compared to placebo group at 6 months after the end of therapy.
Highlights
[Report on the results of the clinical study of the therapeutic effectiveness of the drug ALGIREM in children with influenza and acute respiratory viral infection.
Опыт применения препарата Орвирем при острых респираторных вирусных инфекциях у детей.
Доказана клиническая эффективность препарата при острых респираторных инфекциях (ОРИ) у детей, в том числе с отягощенным аллергоанамнезом.
Summary
[Report on the results of the clinical study of the therapeutic effectiveness of the drug ALGIREM in children with influenza and acute respiratory viral infection. Опыт применения препарата Орвирем при острых респираторных вирусных инфекциях у детей.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
